Two studies released this month have brought into focus the degree to which Americans are turning to illicit substances and alcohol in response to the stress brought on by the COVID-19 pandemic.
Universal Health Services and Eleos Health, a behavioral health tech firm, have announced the launch of a six-week pilot program for clinical decision-support software to analyze patient experiences and treatment outcomes in Nashville.
The FDA will conduct a virtual public meeting on patient-focused drug development for stimulant use disorder on Oct. 6, and is seeking input from individuals and families impacted by stimulant use.
The addition of recovery coaching and the use of a digital breathalyzer test were found to reduce participant attrition rates in an outpatient SUD treatment program.
Six months into the pandemic, the American Society of Addiction Medicine’s task force on caring for patients amid COVID-19 has revised more than 15 guideline documents covering a wide range of operational topics for providers.